The combination of PF-04449913 (Glasdegib) with azacitidine is being explored for its potential to enhance treatment outcomes in higher-risk MDS, AML, and CMML patients. Given the high unmet medical need in these populations, successful results could position Pfizer favorably in the hematological malignancies market, which is characterized by significant competition from existing therapies such as hypomethylating agents and novel agents like venetoclax. The completion of this trial may provide critical data to support regulatory submissions and market access strategies, enhancing Pfizer's portfolio in oncology.